100% Quality Guarantee
PhD-Level Technical Support
Negalstobart Antibody - Bioactivity-binding
Key Features

Negalstobart Antibody (GXBS02200)

SKU GXBS02200
Product Type Research Grade Biosimilar
Antibody Type Monoclonal
Host Species Human
Reactivity Human
Applications ELISA, FCM, Functional assay, Research in vivo, WB
Isotype IgG4-kappa
$677 - $2,208

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Negalstobart Antibody

Negalstobart Antibody is a research-grade biosimilar monoclonal antibody targeting CD223. It is a human IgG4-kappa antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays, in vivo research and Western blot. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.

Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag).

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose